Treatment Options in mCRC: A Clinical Overview

Author(s):

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Melody Chang, RPh, MBA, BCOP

Experts provide an overview of third-line treatment options for metastatic colorectal cancer (mCRC) in patients with disease progression through all available regimens, focusing on fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab.

Now Viewing

EP: 1.Treatment Options in mCRC: A Clinical Overview

EP: 2.Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

EP: 3.Quality of Life and Patient Outcomes in mCRC Treatment

EP: 4.Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP: 5.The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP: 6.Evolution of Oncology Pharmacy Practice in mCRC

EP: 7.Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP: 8.Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP: 9.Best Practices for Overcoming mCRC Prior Authorization Barriers

EP: 10.Building Better Collaboration: Reducing Care Delays in Managing mCRC

Video content above is prompted by the following:

Provide an overview of the third-line treatment options for mCRC for patients with disease that has progressed through all available regimens.
Fruquintinib
Regorafenib
Trifluridine + tipiracil ± bevacizumab

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!